<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue journalpublishing.dtd?><?DTDIdentifier.IdentifierType system?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Vis</journal-id><journal-id journal-id-type="publisher-id">MV</journal-id><journal-title-group><journal-title>Molecular Vision</journal-title></journal-title-group><issn pub-type="epub">1090-0535</issn><publisher><publisher-name>Molecular Vision</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">17563717</article-id><article-id pub-id-type="publisher-id">a73</article-id><article-id pub-id-type="publisher-id">2006MOLVIS</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Role of <italic>CYP1B1</italic>, <italic>MYOC</italic>, <italic>OPTN</italic> and <italic>OPTC</italic> genes in adult-onset primary open-angle glaucoma: predominance of <italic>CYP1B1</italic> mutations in Indian patients</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Kumar</surname><given-names>Arun</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Basavaraj</surname><given-names>Manjunath G.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Gupta</surname><given-names>Santosh K.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Qamar</surname><given-names>Imteyaz</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ali</surname><given-names>Abdullah Mahmood</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bajaj</surname><given-names>Vineeta</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ramesh</surname><given-names>T.K.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Prakash</surname><given-names>D. Ravi</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Shetty</surname><given-names>Jyoti S.</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Dorairaj</surname><given-names>Syril K.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><aff id="aff1"><label>1</label>Department of Molecular Reproduction, Development and Genetics, Indian Institute of Science, Bangalore, India</aff><aff id="aff2"><label>2</label>Minto Ophthalmic Hospital, Bangalore, India</aff><aff id="aff3"><label>3</label>Bangalore West Lions Superspecialty Eye Hospital, Bangalore, India</aff></contrib-group><author-notes><corresp id="cor1">Correspondence to: Dr. Arun Kumar, MRDG, Indian Institute of Science, Bangalore 560012, India; Phone: 91-80-2293 2998; FAX: 91-80-2360 0999; email: <email xlink:href="arunk00@hotmail.com">arunk00@hotmail.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2007</year></pub-date><pub-date pub-type="epub"><day>30</day><month>4</month><year>2007</year></pub-date><volume>13</volume><fpage>667</fpage><lpage>676</lpage><history><date date-type="received"><day>14</day><month>12</month><year>2006</year></date><date date-type="accepted"><day>25</day><month>4</month><year>2007</year></date></history><permissions><copyright-year>2007</copyright-year><copyright-holder>Molecular Vision</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Purpose</title><p>Mutations in the <italic>CYP1B1</italic>, <italic>MYOC</italic>, <italic>OPTN</italic>, and <italic>WDR36</italic> genes result in glaucoma. Given its expression in the optic nerve, it is likely a mutation in the <italic>OPTC</italic> gene is also involved in initiating glaucoma. This study was designed to evaluate the involvement of the <italic>CYP1B1</italic>, <italic>MYOC</italic>, <italic>OPTN</italic>, and <italic>OPTC</italic> genes in the etiology of adult-onset primary open-angle glaucoma (POAG) found in 251 Indian patients.</p></sec><sec><title>Methods</title><p>Blood samples were obtained from individuals for DNA isolation. A combination of polymerase chain reaction-single strand conformation polymorphism, allele-specific PCR, and DNA sequencing techniques were used to detect mutations in four genes. Four microsatellite markers from the <italic>CYP1B1</italic> candidate region and three intragenic <italic>CYP1B1</italic> single nucleotide polymorphisms (SNPs) were used to determine the origin of the most common <italic>CYP1B1</italic> mutations.</p></sec><sec><title>Results</title><p>Three previously known mutations (Pro193Leu, Glu229Lys, and Arg368His) and one novel (Met292Lys) mutation were found in the <italic>CYP1B1</italic> gene. Frequencies of the most common mutations, Glu229Lys and Arg368His, in patients were 5.12% and 3.98%, respectively. The Glu229Lys and Arg368His mutations were also found in normal controls at frequencies of 5% and 2%, respectively, suggesting that these mutations might be polymorphic variants in our population. The absence of allele sharing for D2S177, D2S1346, D2S2974, and D2S2331 markers and three intragenic <italic>CYP1B1</italic> SNPs in patients suggested multiple origins for the Glu229Lys and Arg368His variants. Two of 251 (0.8%) patients had the Gln48His mutation in <italic>MYOC</italic>. There was no difference in the frequency of a <italic>MYOC</italic> -83G&#x0003e;A promoter polymorphism between patients and controls. A novel <italic>OPTN</italic> mutation, Thr202Arg, was detected in one of 251 (0.4%) patients. The <italic>OPTN</italic> variant Met98Lys was detected in similar frequencies in patients and controls. No mutation was detected in <italic>OPTC</italic>. Taken together, 3.59% (9/251) of our POAG patients had mutations in the <italic>CYP1B1</italic>, <italic>MYOC</italic>, and <italic>OPTN</italic> genes.</p></sec><sec><title>Conclusions</title><p>This is the first report to document the involvement of the <italic>CYP1B1</italic>, <italic>MYOC</italic>, and <italic>OPTN</italic> genes in the etiology of POAG in the same set of Indian patients. Our study shows that mutations in these genes are rare in Indian POAG patients.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>GalleyStatus</meta-name><meta-value>Export to XML</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Glaucoma is the leading cause of irreversible blindness and the second leading cause of blindness after cataract, affecting 66 million people worldwide [<xref ref-type="bibr" rid="r1">1</xref>]. Glaucoma is a heterogeneous group of progressive optic neuropathies characterized by an excavation of the optic disc and progressive alteration of the visual field [<xref ref-type="bibr" rid="r2">2</xref>]. High intraocular pressure (IOP), defined as being above 21 mmHg, in both eyes and a positive family history for glaucoma are commonly associated risk factors. Based on the age of onset and other clinical features, glaucoma has been classified into primary congenital glaucoma (PCG), juvenile-onset open-angle glaucoma (JOAG), and adult-onset primary open-angle glaucoma (POAG). PCG manifests at birth or in early infancy (up to 3 years of age). Its phenotype is characterized by elevated IOP, corneal edema, enlargement of the globe (buphthalmos), epiphora, photophobia, and blepharospasm. PCG occurs as a result of developmental anomalies of the anterior chamber angle that prevent drainage of the aqueous humor, thereby elevating IOP. PCG is most commonly inherited as an autosomal recessive trait. JOAG is characterized by early onset (at 10-35 years of age) and autosomal dominant inheritance with high penetrance. POAG occurs after the age of 35 years and is the most common form of glaucoma.</p><p>In a majority of cases, glaucoma does not follow a clear-cut inheritance pattern. However, clustering of multiple affected individuals within families suggests that it has a genetic basis. Linkage analyses have identified 23 loci (GLC1A-GLC1L, GLC3A-GLC3B, 2p14, 2q33-q34, 5q22.1-q32, 10p12-p13, 14q11, 14q21-q22, 17p13, 17q25, and 19q12-q14) for different forms of glaucoma [<xref ref-type="bibr" rid="r3">3</xref>-<xref ref-type="bibr" rid="r10">10</xref>]. However, only four genes (<italic>MYOC</italic>/<italic>TIGR</italic>, <italic>CYP1B1</italic>, <italic>OPTN</italic>, and <italic>WDR36</italic>) have been identified so far [<xref ref-type="bibr" rid="r4">4</xref>,<xref ref-type="bibr" rid="r11">11</xref>-<xref ref-type="bibr" rid="r13">13</xref>]. The myocilin/trabecular meshwork-induced glucocorticoid response protein (<italic>MYOC</italic>/<italic>TIGR</italic>) gene, located at the GLC1A locus on chromosome 1q24.3-q25.2, has been shown to cause glaucoma in 2-4% of POAG cases [<xref ref-type="bibr" rid="r14">14</xref>]. The cytochrome P450 (<italic>CYP1B1</italic>) gene, located at the GLC3A locus on chromosome 2p22-p21, has been shown to cause PCG, JOAG, and POAG [<xref ref-type="bibr" rid="r2">2</xref>,<xref ref-type="bibr" rid="r12">12</xref>,<xref ref-type="bibr" rid="r15">15</xref>]. In a large family in which <italic>MYOC</italic>-linked POAG segregated, a heterozygous mutation in <italic>CYP1B1</italic> was associated with early onset of the disease, indicating that a <italic>CYP1B1</italic> mutation might behave as a modifier of the <italic>MYOC</italic> gene [<xref ref-type="bibr" rid="r15">15</xref>]. The optineurin (<italic>OPTN</italic>) gene, located at the GLC1E locus on chromosome 10p14-p15, has been shown to cause normal tension glaucoma (NTG), a subtype of POAG [<xref ref-type="bibr" rid="r13">13</xref>]. The WD repeat-containing protein 36 (<italic>WDR36</italic>) gene, located at the GLC1G locus on chromosome 5q21.3-q22.1, has been shown to be mutated in POAG [<xref ref-type="bibr" rid="r4">4</xref>].</p><p>Glaucoma is a treatable disease if detected early. Therefore, development of an accurate test for the detection of presymptomatic carriers at risk is important for the management of glaucoma. To this end, a few studies have been carried out to assess the roles of the <italic>MYOC</italic> [<xref ref-type="bibr" rid="r16">16</xref>-<xref ref-type="bibr" rid="r19">19</xref>], <italic>CYP1B1</italic> [<xref ref-type="bibr" rid="r20">20</xref>], and <italic>OPTN</italic> [<xref ref-type="bibr" rid="r21">21</xref>,<xref ref-type="bibr" rid="r22">22</xref>] genes in the etiology of Indian POAG patients from different parts of the country. We have reported the genetic analysis of glaucoma in a large south Indian pedigree [<xref ref-type="bibr" rid="r18">18</xref>]. Moreover, there is no comprehensive study published to date that assesses the roles of three known glaucoma-causing genes (<italic>CYP1B1</italic>, <italic>MYOC</italic>, and <italic>OPTN</italic>) in the same set of Indian POAG patients. In this study, we report mutation analysis of the <italic>CYP1B1</italic>, <italic>MYOC</italic>, and <italic>OPTN</italic> genes in 251 Indian POAG patients from the south Indian state of Karnataka.</p><p>The <italic>OPTC</italic> (opticin) gene encodes a protein that is a member of the small leucine-rich repeat protein (SLRP) family, and is located on chromosome 1q31-q32 within an age-related macular degeneration (AMD) susceptibility locus [<xref ref-type="bibr" rid="r23">23</xref>]. Because of its protein profile in different parts of the eye, such as the iris, trabecular meshwork/ciliary body, retina, vitreous, and optic nerve, Friedman et al. [<xref ref-type="bibr" rid="r23">23</xref>] screened <italic>OPTC</italic> for mutations in individuals with POAG, NTG, and AMD. They failed to find any mutation in this gene. To rule out the <italic>OPTC</italic> gene as a glaucoma gene, we screened this gene in our POAG data set. The results of our analysis are presented herein.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Patients</title><p>A total of 251 patients with adult-onset POAG were evaluated at the Minto Ophthalmic Hospital, and Bangalore West Lions Superspecialty Eye Hospital. Both hospitals are located in the city of Bangalore, Karnataka. The patients were natives of Karnataka and spoke the south Indian Kannada language. They ranged in age from 45 to 65 years. Of the 251 patients, 116 patients received the diagnosis of POAG based on the presence of characteristic glaucomatous optic neuropathy and defects in visual fields. The remaining 135 patients were given the diagnosis of glaucoma based on glaucomatous optic neuropathy only, as visual field defects could not be assessed in these patients due to an advance stage of glaucoma. IOP was more than 21 mmHg in 198 patients. The remaining 53 patients had NTG with IOP below 21 mmHg and significant optic disc damage and visual field defects at the time of diagnosis. All patients had open-angles (Shafer grade greater than III) on gonioscopy and no other eye or systemic abnormalities. Patients with secondary causes of glaucoma (e.g., uveitis, steroid-induced, or trauma) were excluded from this study. We recruited 100 normal controls, also from Karnataka and with the same linguistic background, through several eye care camps. Their ages ranged from 45 to 75 years. All participants went through a detailed clinical examination and were found to have no signs or symptoms of glaucoma or any other eye disease. Controls did not have any family history of glaucoma. Informed consent was obtained from each patient. This study followed the guidelines of the Indian Council of Medical Research, New Delhi.</p></sec><sec><title>Molecular study</title><p>Three to five ml of peripheral blood was collected from each individual in Vacutainer EDTA<sup>TM</sup> tubes (Beckton-Dickinson, Franklin Lakes, NJ). Genomic DNA was isolated from blood samples using a Wizard&#x000ae; genomic DNA extraction kit (Promega, Madison, WI). Mutation analyses of the four genes were carried out using a combination of PCR-SSCP (polymerase chain reaction-single strand conformation polymorphism) and DNA sequencing techniques. For PCR-SSCP, primer sets were designed for the <italic>CYP1B1</italic>, <italic>MYOC</italic>, <italic>OPTN</italic>, and <italic>OPTC</italic> genes, which covered their entire coding regions and intron-exon junctions. The reference mRNA sequences for the <italic>CYP1B1</italic>, <italic>MYOC</italic>, <italic>OPTN</italic>, and <italic>OPTC</italic> genes used were <ext-link ext-link-type="uri" xlink:href="http://www.molvis.org/molvis/external.cgi?gbdna=U03688">U03688</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://www.molvis.org/molvis/external.cgi?gbdna=NM_000261">NM_000261</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://www.molvis.org/molvis/external.cgi?gbdna=AF420371">AF420371</ext-link>, and <ext-link ext-link-type="uri" xlink:href="http://www.molvis.org/molvis/external.cgi?gbdna=NM_014359">NM_014359</ext-link>, respectively. The genomic sequences for these genes were retrieved from the <ext-link ext-link-type="uri" xlink:href="http://genome.ucsc.edu">UCSC Genome Bioinformatics</ext-link> site. Primer details are shown in <xref ref-type="table" rid="t1">Table 1</xref> Since abnormalities in <italic>WDR36</italic> alone are not sufficient to cause POAG [<xref ref-type="bibr" rid="r24">24</xref>], we have not screened this gene for mutations in our POAG samples. In the future, we plan to screen this gene for mutations in our samples. PCR was carried out in a 25 &#x003bc;l reaction volume containing 50-100 ng of genomic DNA, 50 ng of each primer, 0.25 &#x003bc;l of alpha P<sup>32</sup>-dCTP (3,000 Ci/mmole; PerkinElmer, Wellesley, MA), 0.2 mM of each dNTP, and 1 U of <italic>Taq</italic> DNA polymerase (Bangalore Genei<sup>TM</sup>, Bangalore, India) in a standard buffer supplied by the vendor. PCR was carried out in a Thermal Cycler PTC150 (MJ Research, Watertown, MA) under the following conditions: an initial denaturation at 95 &#x000b0;C for 2 min was followed by 35 cycles at 95 &#x000b0;C for 30 s, 55-72 &#x000b0;C for 30 s, 72 &#x000b0;C for 1 min with a final extension at 72 &#x000b0;C for 5 min. Following PCR-SSCP, the gels were dried and subjected to Phosphor Image analysis (Fuji, Kanagawa, Japan). For sequencing, PCR was carried out as aforedescribed but without including alpha P<sup>32</sup>-dCTP in the reaction mixture. PCR amplified products were purified using Auprep<sup>TM</sup> PCR Purification Columns (Invitrogen, Delhi, India) and sequenced on an ABI PRISM A310 automated sequencer (PE Biosystems, Foster City, CA). Since we did not identify the <italic>MYOC</italic> Gln48His mutation reported from India earlier [<xref ref-type="bibr" rid="r19">19</xref>] in our samples by PCR-SSCP analysis, we used allele-specific PCR to screen the samples for the presence of this mutation. The sequence of the common forward primer for allele-specific PCR is as follows: 5'-TGC AAT GAG GTT CTT CTG TGC ACG-3'. The sequences of the reverse allele-specific primers are as follows: 5'(mutant allele)-GAC TGG CCA CAC TGA AGG TAT AA-3' and 5'(wild-type allele)-GAC TGG CCA CAC TGA AGG TAT AC-3'. A 190 bp amplicon was generated with common forward and wild-type/mutant allele primers. Following detection of this mutation in patient samples, PCR products were sequenced to confirm the presence of the mutation. The <italic>MYOC</italic>-83G&#x0003e;A promoter polymorphism was studied by PCR-SSCP analysis. Primer sequences for this polymorphism are as follows: forward 5'-CAG CCT CAC GTG GCC ACC TCT GTC-3' and reverse 5'-AGG CCC AAA GCT GCA GCA ACG TGC-3'. These primers amplify a 196 bp amplicon. In order to see whether there could be a common origin of a specific <italic>CYP1B1</italic> mutation, all patients with the mutation were genotyped with four microsatellite markers from the <italic>CYP1B1</italic> candidate region and three intragenic <italic>CYP1B1</italic> single nucleotide polymorphisms (SNPs). The order of markers with respect to <italic>CYP1B1</italic> is as follows: D2S177-D2S1346-<italic>CYP1B1</italic>-D2S2974-D2S2331 (taken from the <ext-link ext-link-type="uri" xlink:href="http://genome.ucsc.edu">UCSC Genome Bioinformatics</ext-link> site).</p><table-wrap id="t1" position="float"><label>Table 1</label><caption><title>Details of primer sets used in the PCR-SSCP analysis of the <italic>CYP1B1</italic>, <italic>MYOC</italic>, <italic>OPTN</italic>, and <italic>OPTC</italic> genes.</title></caption><table frame="hsides" rules="groups"><col width="52" span="1"/><col width="36" span="1"/><col width="308" span="1"/><col width="58" span="1"/><col width="31" span="1"/><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Gene<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Exon<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Primer sequence (5'-3')<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Amplicon size (bp)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">AT (&#x000b0;C)<hr/></td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"><italic>CYP1B1</italic><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CY2AF:TGTCTCTGCACCCCTGAGTGTCA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">264<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">67<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CY2AR:GAGGTGAGCCGCCTGGCCCAC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CY2BF:TGCTGAGGCAACGGAGGCGGCA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">211<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">68<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CY2BR:TGCACCAGGGCCTGGTGGATGG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CY2CF:TCCAGATCCGCCTGGGCAGCTG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">262<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">67<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CY2CR:CTCAGCACGTGGCCCTCGAGGA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CY2DF:CAGCATGATGCGCAACTTCTTCAC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">254<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">64<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CY2DR:GCGCCCGAACTCTTCGTTGTGGC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CY2EF:TGCCGCTACAGCCACGACGACC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">261<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">64<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CY2ER:GAGGATAAAGGCGTCCATCATGTCG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CY2FF:GACAAGTTCTTGAGGCACTGCGAA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">267<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">66<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CY2FR:TCAGAGGAGAAAAGACCTGGCCCA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CY3AF:GCTCACTTGCTTTTCTCTCTCCAC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">255<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">60<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CY3AR:CCACAGTGTCCTTGGGAATGTGGTA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CY3BF:TCACTATTCCTCATGCCACCACTG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">277<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">60<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CY3BR:TGAGCCAGGATGGAGATGAAGAGA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CY3CF:AAAGGCGGTGCATTGGCGAAGAAC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">291<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">60<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CY3CR:TTACTCCTCATCTCCGAAGATGTGA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"><italic>MYOC</italic><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TG1AF:AAACCTCTCTGGAGCTCGGGCA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">248<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">60<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TG1AR:TATACTGGCATCGGCCACTCTGG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TG1BF:GCCTGCCTGGTGTGGGATGTGG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">255<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">64<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TG1DBR:GGCAGCCTGGTCCAAGGTCAATTGG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TIG1CF:GGAGGCCACCAAAGCTCGACTCA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">212<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">60<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TG1CR:TCTCTTCCTCCAGAACTGACTTGTC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TG1DF:CCAAACCAGAGAGTTGGAGACTGC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">256<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">62<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TG1DR:AGCCATATCACCTGCTGAACTCAGA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TG2F:CTCAACATAGTCAATCCTTGGGCCA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">244<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">60<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TG2R:GACATGAATAAAGACCACGTGGGCA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TIGR1DF:CAAGTATGGTGTGTGGATGCGAGA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">205<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">64<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TIGR1R:GCTCCCCGAGTACACCACAGCA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TIGR1F:GCCAAGCTTCCGCATGATCATTG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">231<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">60<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TIGR1DR:GTGCCAACTGTGTCGATTCTCCA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TIGR2DF:CCTTCTAAGGTTCACATACTGCCTAG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">270<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">66<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TIGR2DR:AATGGCACCTTTGGCCTCATCGGTG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TIGR3F:ACATTGACTTGGCTGTGGATGAAG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">267<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">64<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TIGR3R:ATGGGATGGTCAGGGTCTTGCTG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TIGR4F:ACCTCAGCAGATGCTACCGTCAA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">216<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">64<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TIGR4R:CCATTGCCTGTACAGCTTGGAGG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"><italic>OPTN</italic><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">OPTN4aF:AATCGCCAATGGGTTTGTGGGA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">198<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">64<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">OPTN4aR:ACGTGTCCAGGTTTGGGTGGGC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">OPTN4bF:AGGAGGACAGCCCCAGTGAAAGCAC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">193<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">72<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">OPTN4bR:AGGGATGGCATTTCTTGCAGGCCCA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">OPTN5F:CACTTTCCTGGTGTGTGACTCCATC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">280<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">64<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">OPTN5R:AAAAAACAACATCACAATGGATCGGTC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">OPTN6F:CAGCCTTAGTTTGATCTGTTCATTCAC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">284<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">60<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">OPTN6R:CCAGGGGAGGCTTTATAGTTTGCTC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">OPTN7F:TGGAAGCTTCCTTGGGTTGCATGTC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">275<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">65<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">OPTN7R:AACATTTGACCTCCGGTGACAAGCA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">8<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">OPTN8F:GGTTACTCTCTTCTTAGTCTTTGGAA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">286<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">60<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">OPTN8R:GTATCTTAATTATATCTCAGGAAAGCTG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">OPTN9F:TTCTCTTAAAGCCAAAGAGAAAGTAAC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">232<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">55<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">OPTN9R:CACAAG ATTTGAATTCAGTGGCTGGA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">10<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">OPTN10F:GTTTAATGTCAGATGATAATTGTACAGA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">223<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">58<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">OPTN10R:CTTTGTAAAAATGTATATTTCAAAGGAGG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">11<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">OPTN11F:CGTAAAGGAGCATTGTTTATCCTCA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">264<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">60<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">OPTN11R:CAATCTGTATAAAAAGGCGATTCTCC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">12<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">OPTN12F:GAAGGTTGGGAGGCAAGACTATAAG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">224<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">60<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">OPTN12R:CAACAGTTTCTGTTCATTACTAGGCTA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">13<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">OPTN13F:CAGGCAGAATTATTTCAAAACCATTTCTAG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">252<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">60<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">OPTN13R:CAGGGCTGGCCTCGCTCAGCTGG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">14<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">OPTN14F:TGCATTCATCTAGGTACTAAGTTCTG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">229<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">60<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">OPTN14R:TCTACGGCCATGCTGATGTGAGCT<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">15<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">OPTN15F:GTCTGCTCAGTGTTGTCATGTTTCG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">243<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">60<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">OPTN15R:GAATCCATTGTAGAGAATGAAGTGGAA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">16<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">OPTN16F:CAAGTGAAACAAACACAACTGCCTG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">227<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">60<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">OPTN16R:CTGACATTTACCAACAGTTTTGGGGA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"><italic>OPTC</italic><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">OP2aF:CACTCTGGAGAGCCTGTCCCTCAGA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">227<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">64<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">OP2aR:GAACTTCAAAGGAATCGCCTTCCCTG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">OP2bF:CAGGAGACAGGGACAGCTTCTCTC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">236<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">64<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">OP2bR:CTCCCAGTGTCATGCAGGGAATGTA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">OP3F:TTTGTGCAAAAGCTGGGCTACTGTG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">230<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">60<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">OP3R:GCCTATGACCTAGGGATATTGCGA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">OP4F:GCCCCAGAGGCTAAAGAGATCTCC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">265<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">64<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">OP4R:CAGGGTGGCTGCATATGCCTGC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">OP5F:AAAGATAGTGTGTTCTGGTTTCTCTC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">296<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">64<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">OP5R:GTGGTGGAGGTGATAGATAGTGGA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">OP6F:CCAACAGGACCCACCAGCCTCCTA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">209<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">64<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">OP6R:CTGCTCCTGGTATCTAACTTCCATCC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">OP7F:GGCAGAGCCTCTTGGTGAGGCTCA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">276<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">64<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">OP7R:GGCCCATGCCTGCATGGTCCTTG</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><p>Note that primer sets CY2AF/CY2AR, OPTN4aF/OPTN4aR, and OPTN7F/OPTN7R work with 5% DMSO and 1.5 mM magnesium chloride. Primer sets CY2BF/CY2BR, CY2CF/CY2CR, CY2DF/CY2DR, and CY2EF/CY2ER work with 5% DMSO and 1 mM magnesium chloride. Primer set TG1BF/TG1DBR works with 1 mM magnesium chloride. The rest of the primer sets work with 1.5 mM magnesium chloride. Exon 1 of <italic>CYP1B1</italic>, exons 1, 2, and 3 of <italic>OPTN</italic>, and exon 1 of <italic>OPTC</italic> were not screened for mutations as they are non-coding. AT, annealing temperature.</p></table-wrap-foot></table-wrap></sec></sec><sec sec-type="results|discussion"><title>Results &#x00026; Discussion</title><p>Analysis of the entire coding region of the <italic>CYP1B1</italic> gene in POAG patients revealed four different mutations (c.578C&#x0003e;T/Pro193Leu, c.685G&#x0003e;A/Glu229Lys, c.875T&#x0003e;A/Met292Lys, and c.1103G&#x0003e;A/Arg368His) in 10.76% (27/251) of patients (<xref ref-type="table" rid="t2">Table 2</xref>). Three mutations; Pro193Leu, Glu229Lys, and Arg368His, have been reported earlier in PCG patients from different populations [<xref ref-type="bibr" rid="r25">25</xref>-<xref ref-type="bibr" rid="r27">27</xref>]. The fourth mutation, Met292Lys, is a novel one in exon 2 and fulfills the criteria of a mutation since the methionine residue is conserved across species from human to carp (<xref ref-type="fig" rid="f1">Figure 1A</xref>) and was not found in 97 controls (data not shown). Only patients 119 and 179 were compound heterozygous for Met292Lys/Arg368His and Pro193Leu/Glu229Lys, respectively (<xref ref-type="table" rid="t2">Table 2</xref>). The remaining patients were heterozygous for the Pro193Leu, Glu229Lys, Met292Lys, and Arg368His mutations (<xref ref-type="table" rid="t2">Table 2</xref>). Melki et al. [<xref ref-type="bibr" rid="r2">2</xref>] found that 4.6% (11/236) of French patients with early-onset POAG have mutations in <italic>CYP1B1</italic>. They have reported the Glu229Lys mutation in a heterozygous state. Colomb et al. [<xref ref-type="bibr" rid="r27">27</xref>] found that 6.45% (2/31) of French PCG patients have the Glu229Lys mutation in a heterozygous state. Acharya et al. [<xref ref-type="bibr" rid="r20">20</xref>] observed that 4.5% (9/200) of patients with JOAG from the eastern Indian state of West Bengal have mutations in <italic>CYP1B1</italic>. The Glu229Lys and Arg368His mutations were found in a heterozygous state, and these mutations were not present in 100 ethnically matched controls [<xref ref-type="bibr" rid="r20">20</xref>].</p><table-wrap id="t2" position="float"><label>Table 2</label><caption><title>Previously known and novel mutations detected in the <italic>CYP1B1</italic>, <italic>MYOC</italic>, and <italic>OPTN</italic> genes in primary open-angle glaucoma patients.</title></caption><table frame="hsides" rules="groups"><col width="68" span="1"/><col width="72" span="1"/><col width="82" span="1"/><col width="80" span="1"/><col width="52" span="1"/><col width="234" span="1"/><tbody><tr><td rowspan="2" valign="top" align="center" scope="row" colspan="1">Patient (Age of onset/ diagnosis)<hr/></td><td colspan="3" valign="top" align="center" rowspan="1">Location of mutation<hr/></td><td rowspan="2" valign="top" align="center" colspan="1">IOP (RE:LE)<hr/></td><td rowspan="2" valign="top" align="left" colspan="1">CD (RE/LE) ratio and other clinical details<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1"><italic>MYOC</italic><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><italic>CYPIBI</italic><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><italic>OPTN</italic><hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">4 (53/55)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Arg368His/+<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">13/12<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.9/0.95 BE-not done because of poor vision<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">7 (49/50)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Arg368His/+<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">22/23<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0,6/0.7; RE-upper arcuate defect LE-loss of sensitivity in the lower arcuate region<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">27 (56/57)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Glu229Lys/+<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">14/38<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.5/0.5; BE- reduced sensitivity upper arcuate defect<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">30 (52/53)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Thr202Arg*/+<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">28/22<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.8/0.4; RE-lower arcuate defect with nasal step, LE-loss of sensitivity in the lower arcuate region<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">37 (47/49)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Arg368His/+<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">38/26<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.5/0.3; RE-upper arcuate defect, LE-dense upper and lower arcuate detect going in for tubular vision<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">33 (46/46)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Arg368His/+<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">22/22<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.5/0.6; LE-loss of sensitivity in the lower arcuate region<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">44 (63/70)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Gln48His/+<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">43/48<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.9/0.9S BE-not done because of poor vision<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">54 (55/56)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Glu229Lys/+<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">19/20<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.8/0.7; NTG* BE-upper arcuate defect<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">61 (43/45)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Glu229Lys/+<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">17/18<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.5/0.6; NTG, BE- developing upper arcuate defect<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">66 (48/53)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Glu229Lys/+<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">22/28<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.8/0.9; RE-dense upper and lower arcuate scotoma going in for tubular vision, LE-PL-ve<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">68# (64/65)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Gln48His/+<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">28/32<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.6/0.5; RE-developing lower arcuate scotoma, LE -reduced sensitivity in lower arcuate region<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">69 (48/55)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Arg368His/+<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">21/32<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.9/0.9; BE-not done because of poor vision<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">71 (47/52)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Glu229Lys/+<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">25/23<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.8/0.9; BE-not done because of poor vision<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">79 (45/46)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Glu229Lys/+<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">28/32<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.5/0.6; BE-developing scotoma in the superior arcuate region<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">111 (50/53)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Arg368His/+<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">28/27<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.8/0.7; RE-upper arcuate scotoma, LE -reduced sensitivity in upper arcuate region<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">112 (62/64)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Glu229Lys/+<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">42/39<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.9/0.9; BE-dense upper and lower arcuate scotoma going in for tubular vision<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">119 (55/57)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Arg268His/<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">48/32<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.7/0.7; RE-not done because of poor vision, LE-dense tubular scotoma sparing the central vision<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Met292Lys*<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">120 (55/63)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Met292Lys*/+<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">43/48<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.8/0.9; BE-not done because of poor vision<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">121 (52/60)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Met292Lys*/+<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">48/52<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.9/0.9S BE-not done because of poor vision<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">122 (55/57)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Met292Lys*/+<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">42/33<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.8/0.9; BE-not done because of poor vision<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">131 (57/58)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Glu229Lys/+<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">48/323<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.8/0.8; RE-not done due to poor vision, LE-isolated dense scotoma in (he inferior arena It region with nasal stepping<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">168 (45/47)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Glu229Lys/+<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">28/32<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.9/0.9; RE-dense upper and lower arcuate scotoma going in for tubular vision, LE-PL-ve<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">170 (48/49)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Arg368His/+<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">38/32<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.8/0.9; RE-dense upper and lower arcuate scotoma going in for tubular vision LE-isolated dense scotoma in lower arcuate region with nasal stepping<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">179 (50/52)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Glu229Lys/<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">28/32<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.7/0.7; RE-dense upper arcuate scotoma., LE-PL-ve<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Pro193Leu<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">182 (59/79)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Prol93Leu/+<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">26/24<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.6/0.7; BE- developing upper arcuate defect<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">199 (55/57)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Glu229Lys/+<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">38/22<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.8/0.9; BE-dense upper and lower arcuate scotoma going Lit for tubular vision with macular sptepping<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">202 (50/53)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Arg368His/+<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">16/14<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.6/0.7; NTG, BE- developing lower arcuate defect<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">226 (69/72)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Arg368His/+<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">10/14<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.7/0.6; NTG, BE- developing upper and lower arcuate defect LE-isolated scotoma in die upper arcuate region<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">235 (62/63)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Glu229Lys/+<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">18/12<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.7/0.4; NTG* RE-doublc arcuate scotoma with nasal stepping<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">237 (69/70)</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">Glu229Lys</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">28/26</td><td valign="top" align="left" rowspan="1" colspan="1">0.9/0.9; BE-dense double arcuate scotoma going in for tubular vision</td></tr></tbody></table><table-wrap-foot><p>Shown are details of 30 primary open-angle glaucoma (POAG) patients with previously known and novel mutations in the <italic>CYP1B1</italic>, <italic>MYOC</italic>, and <italic>OPTN</italic> genes. Since the Glu229Lys and Arg368His mutations were found in normal controls with frequencies of 5% and 2%, respectively, these mutations might be polymorphic variants in our population. By excluding these mutations, the frequency of patients with mutations in three glaucoma-causing genes is 3.59% (9/251). In the table, * indicates a novel mutation; + identifies wild-type alleles; # indicates a family history of glaucoma; other cases are sporadic. The following abbreviations were used: normal tension glaucoma (NTG), right eye (RE), left eye (LE), both eyes (BE), perception of light negative (PL-ve), and cup to disc (CD). The age of onset and diagnosis are in years.</p></table-wrap-foot></table-wrap><fig id="f1" fig-type="figure" position="float"><label>Figure 1</label><caption><p>Mutation analysis of the <italic>CYP1B1</italic> and <italic>OPTN</italic> genes. <bold>A</bold>: The left panel shows a sequencing chromatogram from patient 119 who had a novel mutation c.875T&#x0003e;A (Met292Lys) in exon 2 of <italic>CYP1B1</italic>, and the right panel shows conservation of the methionine residue across species. <bold>B</bold>: The left panel presents a sequencing chromatogram from patient 30 who had a novel mutation c.915C&#x0003e;G (Thr202Arg) in exon 7 of <italic>OPTN</italic>, and the right panel shows conservation of the threonine residue across species. Arrows mark positions of nucleotide changes and conserved amino acid residues.</p></caption><graphic xlink:href="mv-v13-667-f1"/></fig><p>Vincent et al. [<xref ref-type="bibr" rid="r15">15</xref>] reported the Arg368His mutation in a heterozygous state along with the <italic>MYOC</italic> Gly399Val mutation in an east Indian/Guyanese family with early-onset glaucoma. Of 30/251 patients with mutations in our samples, 13 patients (5.2%) had the Glu229Lys mutation and 10 patients (3.98%) had the Arg308His mutation (<xref ref-type="table" rid="t2">Table 2</xref>). In order to see whether these mutations were present in normal controls, we screened 100 normal controls. The Glu229Lys and Arg368 mutations were found with frequencies of 5% and 2%, respectively, in normal controls (data not shown), suggesting that these mutations might be polymorphic variants in our population. The presence of the Arg368His mutation in controls is not surprising as Melki et al. [<xref ref-type="bibr" rid="r2">2</xref>] discovered 2.13% (1/47) of French controls with this mutation. The Glu229Lys and Arg368His mutations were the most common mutations in Indian PCG patients with frequencies of 16.22% (6/37) and 59.46% (22/37), respectively [<xref ref-type="bibr" rid="r28">28</xref>]. However, ethnically matched population screening of 140 chromosomes for the <italic>CYP1B1</italic> mutations showed 6.4% and 0.7% carriers for the Glu229Lys and Arg368His mutations, respectively [<xref ref-type="bibr" rid="r28">28</xref>]. The other known mutation, Pro193Leu, was not present in 100 normal controls (data not shown). In order to determine whether the Glu229Lys variant in 13 patients could have a common origin, all patients were genotyped with four microsatellite markers (D2S177-D2S1346-<italic>CYP1B1</italic>-D2S2974-D2S2331) and three intragenic <italic>CYP1B1</italic> SNPs. An absence of allele sharing for the markers in patients suggested that Glu229Lys has multiple origins (<xref ref-type="table" rid="t3">Table 3</xref>). A similar result was obtained for the Arg368His mutation (<xref ref-type="table" rid="t3">Table 3</xref>).</p><table-wrap id="t3" position="float"><label>Table 3</label><caption><title>Genotypes at four microsatellite markers flanking the <italic>CYP1B1</italic> candidate region and three intragenic <italic>CYP1B1</italic> single nucleotide polymorphisms in patients with Glu229Lys and Arg368His variants</title></caption><table frame="hsides" rules="groups"><col width="44" span="1"/><col width="64" span="1"/><col width="50" span="1"/><col width="56" span="1"/><col width="63" span="1"/><col width="59" span="1"/><col width="66" span="1"/><col width="56" span="1"/><col width="56" span="1"/><tbody><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">Patient<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Variant<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">D2S177<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">D2S1346<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">C.142C&#x0003e;G<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">c.355G&#x0003e;T<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">c.1294G&#x0003e;C<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">D2S2974<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">D2S2331<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">27<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Glu229Lys<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1 5<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2 3<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">C G<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">G T<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">CC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1 2<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2 4<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">54<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Glu229Lys<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">4 4<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1 2<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">GG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">TT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">CC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1 2<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">4 5<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">61<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Glu229Lys<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">4 6<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">4 4<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">C G<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">GT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">CC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2 2<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3 6<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">66<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Glu229Lys<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2 5<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2 4<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">CG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">GT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">CG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2 2<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3 4<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">73<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Glu229Lys<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">4 9<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2 2<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">C C<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">GT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">C G<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2 2<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">4 7<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">79<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Glu229Lys<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">4 5<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3 4<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">GG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">TT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">CC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2 2<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">4 7<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">112<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Glu229Lys<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">4 5<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2 4<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">CG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">GT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">CC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1 2<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">7 8<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">131<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Glu229Lys<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">4 5<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2 5<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">C G<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">GT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">CC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2 2<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">7 10<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">I6S<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Glu229Lys<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">5 7<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2 2<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">CG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">GT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">CC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2 2<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">4 7<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">179<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Glu229Lys<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3 3<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3 4<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">CG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">GT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">CG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2 2<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3 8<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">199<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Glu229Lys<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">6 7<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">4 4<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">CG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">GT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">CC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2 2<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3 4<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">235<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Glu229Lys<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">7 9<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2 3<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">CG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">GT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">CC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2 2<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3 7<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">237<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Glu229Lys<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3 3<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">4 5<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">CG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">GT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">CG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2 3<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3 7<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">4<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Arg368His<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">6 8<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2 6<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">CG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">GT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">CC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1 2<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">4 5<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">7<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Arg368His<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2 3<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2 2<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">CC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">GG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">CG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2 2<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1 3<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">37<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Arg368His<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3 3<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1 1<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">CG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">GT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">CG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2 3<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">8 9<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">38<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Arg368His<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">4 4<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1 6<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">CC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">GG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">CG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2 2<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">4 5<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">69<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Arg368His<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3 4<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1 1<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">CG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">GT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">C G<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3 3<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">4 5<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">111<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Arg368His<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">5 6<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1 1<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">CG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">GT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">C G<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2 3<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">4 5<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">119<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Arg368His<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">4 5<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2 4<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">CG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">GT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">CG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2 3<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3 5<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">170<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Arg368His<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3 8<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2 2<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">CG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">GT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">CG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2 2<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">4 7<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">202<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Arg368His<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3 4<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1 4<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">CC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">GG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">CG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1 2<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">5 6<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">226</td><td valign="top" align="center" rowspan="1" colspan="1">Arg36SIIis</td><td valign="top" align="center" rowspan="1" colspan="1">3 8</td><td valign="top" align="center" rowspan="1" colspan="1">4 4</td><td valign="top" align="center" rowspan="1" colspan="1">CG</td><td valign="top" align="center" rowspan="1" colspan="1">GT</td><td valign="top" align="center" rowspan="1" colspan="1">C G</td><td valign="top" align="center" rowspan="1" colspan="1">2 2</td><td valign="top" align="center" rowspan="1" colspan="1">5 6</td></tr></tbody></table><table-wrap-foot><p>Each number under a microsatellite marker column represents an allele. As can be seen from the genotypes at four microsatellite marker loci, some patients with either of the variants did not share alleles. For example, patients 168 and 179 with Glu229Lys did not share alleles at D2S177, D2S1346, and D2S2331. Although single nucleotide polymorphisms (SNPs) are less polymorphic than microsatellite markers, patients 54 and 73 did not share alleles at c.142C&#x0003e;G. Similarly, patients 7 and 38 with Arg368His did not share alleles at D2S177, D2S1346, and D2S2331. However, alleles at three SNP loci were not useful to determine nonsharing of alleles for Arg368His. Overall, the results suggest multiple origins for both variants.</p></table-wrap-foot></table-wrap><p>In addition to mutations, nine <italic>CYP1B1</italic> population variants and polymorphisms were also identified in our samples, including two novel SNPs (<xref ref-type="table" rid="t4">Table 4</xref>). It is interesting to note that c.142C&#x0003e;G (Arg48Gly) and c.355G&#x0003e;T (Ala119Ser) occurred at a high frequency and were in complete linkage disequilibrium (<xref ref-type="table" rid="t4">Table 4</xref>). Similarly, c.1294G&#x0003e;C (Val432Leu) and c.1347T&#x0003e;C (Asp449Asp) also occurred at a high frequency and were in complete linkage disequilibrium (<xref ref-type="table" rid="t4">Table 4</xref>). Interestingly, c.142C&#x0003e;G (Arg48Gly) and c.355G&#x0003e;T (Ala119Ser) always occurred with c.1294G&#x0003e;C (Val432Leu) and c.1347T&#x0003e;C (Asp449Asp) in patients. Similar results were obtained in JOAG patients and normal controls from the east Indian state of West Bengal (<xref ref-type="table" rid="t5">Table 5</xref>) [<xref ref-type="bibr" rid="r20">20</xref>]. The significance of this phenomenon is not clear at present.</p><table-wrap id="t4" position="float"><label>Table 4</label><caption><title>Polymorphisms and population variants observed in the <italic>CYP1B1</italic>, <italic>MYOC</italic>, <italic>OPTN</italic>, and <italic>OPTC</italic> genes in primary open-angle glaucoma patients and controls</title></caption><table frame="hsides" rules="groups"><col width="50" span="1"/><col width="180" span="1"/><col width="36" span="1"/><col width="54" span="1"/><col width="106" span="1"/><col width="129" span="1"/><tbody><tr><td rowspan="2" valign="top" align="center" scope="row" colspan="1"><bold>Gene</bold><hr/></td><td rowspan="2" valign="top" align="left" colspan="1"><bold>Polymorphism/ population variant</bold><hr/></td><td rowspan="2" valign="top" align="center" colspan="1"><bold>Exon</bold><hr/></td><td rowspan="2" valign="top" align="center" colspan="1"><bold>Intron</bold><hr/></td><td colspan="2" valign="top" align="center" rowspan="1"><bold>Frequency in</bold><hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1"><bold>POAG patients</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>Controls</bold><hr/></td></tr><tr><td rowspan="9" valign="top" align="center" scope="row" colspan="1"><italic>CYPIBI</italic><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">C.IVS1-120T<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2/251 (0.80%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">c.IVS 1-14-15delTC**<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2/251 (0.80%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">c.I42C&#x0003e;G(Arg48Gly)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">165/251 (65.74%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">c.355G&#x0003e;T(Alall9Ser)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">165/251 (65.74%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">c.729G&#x0003e;C (Val243Val)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2/251 (0.80%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">c.l294G&#x0003e;C(Val432Lcu)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">228/251 (90.84%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">c.l347T&#x0003e;C(Asp449Asp)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">228/251 (90.84%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">c.l358A&#x0003e;G(Asn453Ser)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">116/251 (46.22%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">c. 14460G (Leu482Leu)**<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1/251 (0.40%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0/93 (0.0%)<hr/></td></tr><tr><td rowspan="5" valign="top" align="center" scope="row" colspan="1"><italic>MYOC</italic><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-83G&#x0003e;A (Promoter region)#<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">89/116(76.72%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">75/98 (76.53%)<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">c.227G&#x0003e;A (Arg76Lys)#<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">89/116(76.72%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">74/97 (76.29%)<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">c.366C&#x0003e;T(Glyl22Gly)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1/251 (0.40%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">c.l041T&#x0003e;C(Tyr347Tyr)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">9/251 (3.59%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">c.l303T(Gly434Gly)**<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1/251 (0.40%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td></tr><tr><td rowspan="7" valign="top" align="center" scope="row" colspan="1"><italic>OPTN</italic><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">c.412G&#x0003e;A (Thr94Thr)**<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">29/251 (11.55%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">23/50 (46%)<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">c.603T&#x0003e;A (Met98Lys)*<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">20/251 (7.97%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">7/96 (7.29%)<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">C.7120T (Alal34Ala)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1/251 (0.40%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">IVS7-5T&#x0003e;C**<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">7<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">83/251 (33.07%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">11/50 (22%)<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">1VS7-10G&#x0003e;A88<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">7<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1/251 (0.40%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0/50 (0.0%)<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">IVS7+24G&#x0003e;A<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">7<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">36/251 (14.34%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">c.l866G&#x0003e;A(Ser519Ser)**<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">15<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2/251 (0.80%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">11/50 (22%)<hr/></td></tr><tr><td rowspan="5" valign="top" align="center" scope="row" colspan="1"><italic>OPTC</italic></td><td valign="top" align="left" rowspan="1" colspan="1">c.486C&#x0003e;T (Phel62Phe)**<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1/251 (0.40%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0/50 (0.0%)<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">c.803T&#x0003e;C (Leu268Pro)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">31/251 (12.35%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">c.810G&#x0003e;A(Leu270Leu)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">5/251 (1.99%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">-<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">c.859G&#x0003e;A (Val287Met)**<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1/251 (0.40%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0/50 (0.0%)<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">IVS2-150A**</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">1/251 (0.40%)</td><td valign="top" align="center" rowspan="1" colspan="1">-</td></tr></tbody></table><table-wrap-foot><p>Shown are the frequencies of polymorphisms and population variants in the <italic>CYP1B1</italic>, <italic>MYOC</italic>, <italic>OPTN</italic>, and <italic>OPTC</italic> genes seen in primary open-angle glaucoma (POAG) patients and controls. In the table, * indicates a risk factor, ** notes a novel single nucleotide polymorphism (SNP), and # highlights two polymorphisms, -83G&#x0003e;A and Arg76Lys, that were detected in high frequencies in 116 patients and thus were not screened in the remainder of the 251 patients.</p></table-wrap-foot></table-wrap><table-wrap id="t5" position="float"><label>Table 5</label><caption><title>Reported frequencies of known polymorphisms and population variants in the <italic>CYP1B1</italic>, <italic>MYOC</italic>, <italic>OPTN</italic>, and <italic>OPTC</italic> genes in primary open-angle glaucoma patients and controls from different populations</title></caption><table frame="hsides" rules="groups"><col width="52" span="1"/><col width="146" span="1"/><col width="43" span="1"/><col width="58" span="1"/><col width="148" span="1"/><col width="119" span="1"/><tbody><tr><td rowspan="2" valign="top" align="left" scope="row" colspan="1">Gene<hr/></td><td rowspan="2" valign="top" align="left" colspan="1">Polymorphism/ population variant<hr/></td><td colspan="3" valign="top" align="left" rowspan="1">Frequency in population<hr/></td><td rowspan="2" valign="top" align="left" colspan="1">Reference<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">POAG (%)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Controls (%)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Population<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><italic>CYP1B1</italic><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">C.IVS1-120T<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">23<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">22<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Eastern India<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Acharya etal [<xref ref-type="bibr" rid="r20">20</xref>].<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">c.I42C&#x0003e;G(Arg48Gly)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">43.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">39<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Eastern India<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Acharya et al. [<xref ref-type="bibr" rid="r20">20</xref>]<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">c.355G&#x0003e;T(Alall9Ser)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">43.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">39<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Eastern India<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Acharya et al. [<xref ref-type="bibr" rid="r20">20</xref>]<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">c.729G&#x0003e;C (Val243Val)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1.27<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">4.26<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">France<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Mclki etal [<xref ref-type="bibr" rid="r2">2</xref>].<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">c.l294G&#x0003e;C(Val432Leu)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">51<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">59<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Eastern India<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Acharya et al. [<xref ref-type="bibr" rid="r20">20</xref>]<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">c.l347T&#x0003e;C(Asp449Asp)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">51<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">60<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Eastern India<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Acharya et al. [<xref ref-type="bibr" rid="r20">20</xref>]<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">C.1358A&#x0003e;G (Asn453Ser)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">16.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">14<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Eastern India<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Acharya et al. [<xref ref-type="bibr" rid="r20">20</xref>]<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><italic>MYOC</italic><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">-83G&#x0003e;A (Promoter region)*<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">18<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">23<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">U.S.A.<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Alwardet al [<xref ref-type="bibr" rid="r29">29</xref>].<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">30<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">39<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Japan<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Suzuki et al. [<xref ref-type="bibr" rid="r41">41</xref>]<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">73.2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">68.62<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Eastern India<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Mukhopadhyy et al. [<xref ref-type="bibr" rid="r16">16</xref>]<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">c.227G&#x0003e;A (Arg76Lys)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">19<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">18.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">U.S.A.<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Alwardet al [<xref ref-type="bibr" rid="r29">29</xref>].<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">73.2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">68.62<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Eastern India<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Mukhopadhyy et al. [<xref ref-type="bibr" rid="r16">16</xref>]<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">c.366C&#x0003e;T(Glyl22GIy)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.53<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">U.S.A.<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Alwardetal [<xref ref-type="bibr" rid="r29">29</xref>].<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">c.l041T&#x0003e;C(Tyr347Tyr)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">5.4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">7.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">U.S.A<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Alward et al. [<xref ref-type="bibr" rid="r29">29</xref>]<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><italic>OPTN</italic><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">c.603T&#x0003e;A (Mel98Lys)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">28.6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">24.6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">China<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Leung et al. [<xref ref-type="bibr" rid="r36">36</xref>]<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">13.6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">2.1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">U.S.A.<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Rezaieetal [<xref ref-type="bibr" rid="r13">13</xref>].<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">11<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">5.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Eastern India<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Mukhopadhyay et al. [<xref ref-type="bibr" rid="r21">21</xref>]<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">4.1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">South Indian state of Tamil Nadu<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Sripriya et al. [<xref ref-type="bibr" rid="r22">22</xref>]<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">16.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Japan<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Fuseet al [<xref ref-type="bibr" rid="r33">33</xref>].<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">6.25<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Germany<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Weisschuh et al. [<xref ref-type="bibr" rid="r35">35</xref>]<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">4.64<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">4.54<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">France<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Mclki et al. [<xref ref-type="bibr" rid="r39">39</xref>]<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">10.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">8.33<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Morocco<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Melki et. al. [<xref ref-type="bibr" rid="r39">39</xref>]<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">13.33<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">13.78<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Japan<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Toda ct al [<xref ref-type="bibr" rid="r37">37</xref>].<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">20.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">9.0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Japan<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Alwardet al [<xref ref-type="bibr" rid="r38">38</xref>].<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">c.712C&#x0003e;A (Alal34Ala)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1.75<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.92<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Afro-Caribbean Jewish/Scottish/African Somalian<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Willoughby et al. [<xref ref-type="bibr" rid="r42">42</xref>]<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">IVS7+24G&#x0003e;A<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">10.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">China<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Leung et al. [<xref ref-type="bibr" rid="r36">36</xref>]<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><italic>OPTC</italic><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">c.803T&#x0003e;C (Leu268Pro)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">6.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">14.55<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">French-Canada<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Friedman ct al [<xref ref-type="bibr" rid="r23">23</xref>].<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">c.810G&#x0003e;A (Leu270Leu)</td><td valign="top" align="left" rowspan="1" colspan="1">0.0</td><td valign="top" align="left" rowspan="1" colspan="1">3.66</td><td valign="top" align="left" rowspan="1" colspan="1">French-Canada</td><td valign="top" align="left" rowspan="1" colspan="1">Friedman ct al [<xref ref-type="bibr" rid="r23">23</xref>].</td></tr></tbody></table><table-wrap-foot><p>We did not look for another <italic>MYOC</italic> promoter polymorphism at nt -1000 (-1000C&#x0003e;G; <italic>MYOC.mt1</italic>; asterisk) in our primary open-angle glaucoma (POAG) data set because Alward et al. [<xref ref-type="bibr" rid="r43">43</xref>] and &#x000d6;zg&#x000fc;l et al. [<xref ref-type="bibr" rid="r44">44</xref>] have observed that it is not a risk factor for the development of glaucoma in patients from the U.S.A. or Turkey, respectively.</p></table-wrap-foot></table-wrap><p>Analysis of the <italic>MYOC</italic> gene revealed that 2/251 (0.8%) patients had the Gln48His mutation in a heterozygous state. This mutation was not present in 100 normal controls (data not shown). No other mutation was detected in our samples. The Gln48His mutation has been detected in 4/200 (2%) POAG patients in a heterozygous state from West Bengal [<xref ref-type="bibr" rid="r19">19</xref>]. This mutation has also been detected in 5/200 (2.5%) PCG patients [<xref ref-type="bibr" rid="r19">19</xref>]. Previously, we detected a novel Pro274Arg mutation in a four-generation family with members affected with JOAG and POAG, and with one severely affected patient being homozygous for the mutation [<xref ref-type="bibr" rid="r18">18</xref>]. Overall, the frequency of <italic>MYOC</italic> mutations has been found to be 2-4% in different populations [<xref ref-type="bibr" rid="r14">14</xref>]. Kanagavalli et al. [<xref ref-type="bibr" rid="r17">17</xref>] noted 1.87% (2/107) of patients with POAG from the south Indian state of Tamilnadu who had mutations in the <italic>MYOC</italic> gene. However, Mukhopadhyay et al. [<xref ref-type="bibr" rid="r16">16</xref>] discovered a higher frequency (7.14% or 4/56) of POAG patients from West Bengal with <italic>MYOC</italic> mutations. This could be a statistical anomaly due to a small sample size or a true pattern representative of different geographic origins.</p><p>The <italic>MYOC</italic> promoter polymorphism at -83G&#x0003e;A was initially reported from Western countries ([<xref ref-type="bibr" rid="r14">14</xref>,<xref ref-type="bibr" rid="r29">29</xref>] <xref ref-type="table" rid="t5">Table 5</xref>). This polymorphism has been also observed in Hong Kong and the Philippines [<xref ref-type="bibr" rid="r30">30</xref>,<xref ref-type="bibr" rid="r31">31</xref>]. Alward et al. [<xref ref-type="bibr" rid="r29">29</xref>] suggested that it is unlikely to be a disease-causing mutation. Since this polymorphism was detected in many countries, we wanted to determine its prevalence in our patient and control samples. We did not find any significant difference in the frequency of -83G&#x0003e;A between POAG samples and controls (76.72% in POAG versus 76.53% in controls; <xref ref-type="table" rid="t4">Table 4</xref>). This is similar to the earlier report from West Bengal by Mukhopadhyay et al. [<xref ref-type="bibr" rid="r16">16</xref>]. Interestingly, -83G&#x0003e;A is in linkage disequilibrium with Arg76Lys both in patients and controls (<xref ref-type="table" rid="t4">Table 4</xref> and <xref ref-type="table" rid="t5">Table 5</xref>), suggesting that the -83G&#x0003e;A polymorphism is not a risk factor for developing glaucoma in Indians. Taken together, our observations suggest that mutations in <italic>MYOC</italic> gene may not be a major factor in the appearance of the POAG phenotype in India.</p><p>Mutation analysis of the entire <italic>OPTN</italic> gene revealed that one patient (0.40%) was heterozygous for a novel mutation, Thr202Arg (c.915C&#x0003e;G) in exon 7 (<xref ref-type="fig" rid="f1">Figure 1B</xref>, <xref ref-type="table" rid="t2">Table 2</xref>). This mutation fulfills the criteria of a mutation because it is not present in 93 controls (data not shown) and the threonine residue is conserved in human, macaque, mouse, and rat (<xref ref-type="fig" rid="f1">Figure 1B</xref>). Sripriya et al. [<xref ref-type="bibr" rid="r22">22</xref>] recently screened the <italic>OPTN</italic> gene in 100 high tension glaucoma patients from another south Indian state, Tamilnadu, and did not detect any mutation. Mukhopadhyay et al. [<xref ref-type="bibr" rid="r21">21</xref>] screened the entire coding region of this gene and detected 6/200 (3%) POAG patients from West Bengal, who were heterozygous for the Arg545Gln mutation in exon 16. As observed in other populations [<xref ref-type="bibr" rid="r32">32</xref>-<xref ref-type="bibr" rid="r36">36</xref>], the present observation also suggests that <italic>OPTN</italic> mutations are rare in POAG patients. A total of eight mutations (Glu50Lys, c.691-692insAG, Arg545Gln, Ala336Gly, Ala377Thr, His26Asp, His486Arg, and Glu104Asp) have been reported in the <italic>OPTN</italic> gene from different populations, including the His486Arg mutation in a JOAG patient [<xref ref-type="bibr" rid="r13">13</xref>,<xref ref-type="bibr" rid="r21">21</xref>,<xref ref-type="bibr" rid="r32">32</xref>-<xref ref-type="bibr" rid="r36">36</xref>]. Interestingly, one of the three mutations, Arg545Gln (c.1944G&#x0003e;A), reported by Rezaie et al. [<xref ref-type="bibr" rid="r13">13</xref>], has been detected in similar frequencies in Japanese glaucoma patients and control subjects [<xref ref-type="bibr" rid="r37">37</xref>]. Alward et al. [<xref ref-type="bibr" rid="r38">38</xref>] commented that the Arg545Gln variation is likely to be a nondisease-causing polymorphism. With the Thr202Arg mutation identified in this study, the total number of <italic>OPTN</italic> mutations, excluding Arg545Gln, reaches eight.</p><p>Rezaie et al. [<xref ref-type="bibr" rid="r13">13</xref>] initially reported that Met98Lys (c.603T&#x0003e;A) is a risk-associated alteration (risk factor) for developing glaucoma. They found this variant in both affected individuals and controls, but it was more common in affected individuals than in controls (13.6% versus 2.1%). Alward et al. [<xref ref-type="bibr" rid="r38">38</xref>] and Fuse et al. [<xref ref-type="bibr" rid="r33">33</xref>] showed a significant association between Met98Lys and glaucoma in Japanese patients. On the other hand, Toda et al. [<xref ref-type="bibr" rid="r37">37</xref>] found similar frequencies of Met98Lys in Japanese glaucoma patients and controls. Interestingly, Met98Lys has been shown to be a polymorphic variant in German, French, and Moroccan patients [<xref ref-type="bibr" rid="r35">35</xref>,<xref ref-type="bibr" rid="r39">39</xref>]. Sripriya et al. [<xref ref-type="bibr" rid="r22">22</xref>] did not detect Met98Lys in 100 controls, although it was present in 7/170 (4.1%) POAG and 3/50 (6%) NTG patients from Tamilnadu. However, a statistical analysis did not show any significant correlation with clinical parameters [<xref ref-type="bibr" rid="r22">22</xref>]. In another study by Mukhopadhyay et al. [<xref ref-type="bibr" rid="r21">21</xref>], the frequency of Met98Lys was found to be 11% and 5.5% in POAG and controls from West Bengal, respectively. Sripriya et al. [<xref ref-type="bibr" rid="r22">22</xref>] found Met98Lys in 6% of NTG patients, whereas Mukhopadhyay et al. [<xref ref-type="bibr" rid="r21">21</xref>] failed to find it in NTG patients. In our dataset, the frequency of this variant was found to be similar in our POAG samples and controls (7.97% in POAG versus 7.29% in controls; <xref ref-type="table" rid="t4">Table 4</xref>), suggesting that it may not be a risk factor for developing glaucoma in Indian populations.</p><p>Mutation analysis of the <italic>OPTC</italic> gene did not detect any mutation in our POAG samples. Screening of the <italic>OPTC</italic> gene was carried out in POAG cases by Friedman et al. [<xref ref-type="bibr" rid="r23">23</xref>]. The Leu268Pro polymorphism, identified by Friedman et al. [<xref ref-type="bibr" rid="r23">23</xref>] in 6/87 (6.9%) of POAG/NTG patients and in 8/55 (14.55%) of controls (<xref ref-type="table" rid="t5">Table 5</xref>), was found in 31/251 (12.35%) of our POAG samples (<xref ref-type="table" rid="t4">Table 4</xref>). Another synonymous codon change Leu270Leu, identified by Friedman et al. [<xref ref-type="bibr" rid="r23">23</xref>] in 2/55 (3.66%) of controls (<xref ref-type="table" rid="t5">Table 5</xref>), was also detected in 5/251 (1.99%) of our POAG samples (<xref ref-type="table" rid="t4">Table 4</xref>).</p><p>In summary, 3.59% (9/251) of our POAG patients had mutations in the <italic>CYP1B1</italic>, <italic>MYOC</italic>, and <italic>OPTN</italic> genes. Two previously known <italic>CYP1B1</italic> mutations, Glu229Lys and Arg368His, were found in similar frequencies in POAG patients and controls, suggesting that these mutations might be polymorphic variants in our population. A similar situation exists for the <italic>CYP1B1</italic> Ala443Gly mutation, first reported by Melki et al. [<xref ref-type="bibr" rid="r2">2</xref>] in French patients, and was found to be a polymorphic variant in an Ethiopian population with a frequency of 7% [<xref ref-type="bibr" rid="r40">40</xref>]. No association was found between the <italic>OPTN</italic> Met98Lys variant and glaucoma. Mutations in <italic>MYOC</italic> and <italic>OPTN</italic> are rare in Indian POAG patients. This is the first study to document the prevalence of mutations in three glaucoma-causing genes in the same set of Indian POAG patients. Our study suggests that mutations in these genes are rare in Indian POAG patients.</p></sec></body><back><ack><title>Acknowledgements</title><p>We thank the patients, their family members, and our controls for participating in this study. This study was supported by a grant from the Council of Scientific and Industrial Research, New Delhi. We thank Ms. S. Bhattacharjee for technical help and Dr. V. Meera and Dr. N. Savitha for their help in patient recruitment. We thank Prof. V. Nanjundiah for reading the manuscript and for valuable advice. Finally, we also thank two anonymous reviewers for their valuable suggestions to improve the manuscript.</p></ack><ref-list><title>References</title><ref id="r1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quigley</surname><given-names>HA</given-names></name></person-group><article-title>Number of people with glaucoma worldwide.</article-title><source>Br J Ophthalmol</source><year>1996</year><volume>80</volume><fpage>389</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">8695555</pub-id></mixed-citation></ref><ref id="r2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melki</surname><given-names>R</given-names></name><name><surname>Colomb</surname><given-names>E</given-names></name><name><surname>Lefort</surname><given-names>N</given-names></name><name><surname>Brezin</surname><given-names>AP</given-names></name><name><surname>Garchon</surname><given-names>HJ</given-names></name></person-group><article-title>CYP1B1 mutations in French patients with early-onset primary open-angle glaucoma.</article-title><source>J Med Genet</source><year>2004</year><volume>41</volume><fpage>647</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">15342693</pub-id></mixed-citation></ref><ref id="r3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weisschuh</surname><given-names>N</given-names></name><name><surname>Schiefer</surname><given-names>U</given-names></name></person-group><article-title>Progress in the genetics of glaucoma.</article-title><source>Dev Ophthalmol</source><year>2003</year><volume>37</volume><fpage>83</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">12876831</pub-id></mixed-citation></ref><ref id="r4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monemi</surname><given-names>S</given-names></name><name><surname>Spaeth</surname><given-names>G</given-names></name><name><surname>DaSilva</surname><given-names>A</given-names></name><name><surname>Popinchalk</surname><given-names>S</given-names></name><name><surname>Ilitchev</surname><given-names>E</given-names></name><name><surname>Liebmann</surname><given-names>J</given-names></name><name><surname>Ritch</surname><given-names>R</given-names></name><name><surname>Heon</surname><given-names>E</given-names></name><name><surname>Crick</surname><given-names>RP</given-names></name><name><surname>Child</surname><given-names>A</given-names></name><name><surname>Sarfarazi</surname><given-names>M</given-names></name></person-group><article-title>Identification of a novel adult-onset primary open-angle glaucoma (POAG) gene on 5q22.1.</article-title><source>Hum Mol Genet</source><year>2005</year><volume>14</volume><fpage>725</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">15677485</pub-id></mixed-citation></ref><ref id="r5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allingham</surname><given-names>RR</given-names></name><name><surname>Wiggs</surname><given-names>JL</given-names></name><name><surname>Hauser</surname><given-names>ER</given-names></name><name><surname>Larocque-Abramson</surname><given-names>KR</given-names></name><name><surname>Santiago-Turla</surname><given-names>C</given-names></name><name><surname>Broomer</surname><given-names>B</given-names></name><name><surname>Del Bono</surname><given-names>EA</given-names></name><name><surname>Graham</surname><given-names>FL</given-names></name><name><surname>Haines</surname><given-names>JL</given-names></name><name><surname>Pericak-Vance</surname><given-names>MA</given-names></name><name><surname>Hauser</surname><given-names>MA</given-names></name></person-group><article-title>Early adult-onset POAG linked to 15q11-13 using ordered subset analysis.</article-title><source>Invest Ophthalmol Vis Sci</source><year>2005</year><volume>46</volume><fpage>2002</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">15914615</pub-id></mixed-citation></ref><ref id="r6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiggs</surname><given-names>JL</given-names></name><name><surname>Lynch</surname><given-names>S</given-names></name><name><surname>Ynagi</surname><given-names>G</given-names></name><name><surname>Maselli</surname><given-names>M</given-names></name><name><surname>Auguste</surname><given-names>J</given-names></name><name><surname>Del Bono</surname><given-names>EA</given-names></name><name><surname>Olson</surname><given-names>LM</given-names></name><name><surname>Haines</surname><given-names>JL</given-names></name></person-group><article-title>A genomewide scan identifies novel early-onset primary open-angle glaucoma loci on 9q22 and 20p12.</article-title><source>Am J Hum Genet</source><year>2004</year><volume>74</volume><fpage>1314</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">15108121</pub-id></mixed-citation></ref><ref id="r7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baird</surname><given-names>PN</given-names></name><name><surname>Foote</surname><given-names>SJ</given-names></name><name><surname>Mackey</surname><given-names>DA</given-names></name><name><surname>Craig</surname><given-names>J</given-names></name><name><surname>Speed</surname><given-names>TP</given-names></name><name><surname>Bureau</surname><given-names>A</given-names></name></person-group><article-title>Evidence for a novel glaucoma locus at chromosome 3p21-22.</article-title><source>Hum Genet</source><year>2005</year><volume>117</volume><fpage>249</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">15906098</pub-id></mixed-citation></ref><ref id="r8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>DY</given-names></name><name><surname>Fan</surname><given-names>BJ</given-names></name><name><surname>Chua</surname><given-names>JK</given-names></name><name><surname>Tam</surname><given-names>PO</given-names></name><name><surname>Leung</surname><given-names>CK</given-names></name><name><surname>Lam</surname><given-names>DS</given-names></name><name><surname>Pang</surname><given-names>CP</given-names></name></person-group><article-title>A genome-wide scan maps a novel juvenile-onset primary open-angle glaucoma locus to 15q.</article-title><source>Invest Ophthalmol Vis Sci</source><year>2006</year><volume>47</volume><fpage>5315</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">17122119</pub-id></mixed-citation></ref><ref id="r9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pang</surname><given-names>CP</given-names></name><name><surname>Fan</surname><given-names>BJ</given-names></name><name><surname>Canlas</surname><given-names>O</given-names></name><name><surname>Wang</surname><given-names>DY</given-names></name><name><surname>Dubois</surname><given-names>S</given-names></name><name><surname>Tam</surname><given-names>PO</given-names></name><name><surname>Lam</surname><given-names>DS</given-names></name><name><surname>Raymond</surname><given-names>V</given-names></name><name><surname>Ritch</surname><given-names>R</given-names></name></person-group><article-title>A genome-wide scan maps a novel juvenile-onset primary open angle glaucoma locus to chromosome 5q.</article-title><source>Mol Vis</source><year>2006</year><volume>12</volume><fpage>85</fpage><lpage>92</lpage><ext-link ext-link-type="uri" xlink:href="http://www.molvis.org/molvis/v12/a9/">http://www.molvis.org/molvis/v12/a9/</ext-link><pub-id pub-id-type="pmid">16518310</pub-id></mixed-citation></ref><ref id="r10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>BJ</given-names></name><name><surname>Wang</surname><given-names>DY</given-names></name><name><surname>Lam</surname><given-names>DS</given-names></name><name><surname>Pang</surname><given-names>CP</given-names></name></person-group><article-title>Gene mapping for primary open angle glaucoma.</article-title><source>Clin Biochem</source><year>2006</year><volume>39</volume><fpage>249</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">16332362</pub-id></mixed-citation></ref><ref id="r11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stone</surname><given-names>EM</given-names></name><name><surname>Fingert</surname><given-names>JH</given-names></name><name><surname>Alward</surname><given-names>WL</given-names></name><name><surname>Nguyen</surname><given-names>TD</given-names></name><name><surname>Polansky</surname><given-names>JR</given-names></name><name><surname>Sunden</surname><given-names>SL</given-names></name><name><surname>Nishimura</surname><given-names>D</given-names></name><name><surname>Clark</surname><given-names>AF</given-names></name><name><surname>Nystuen</surname><given-names>A</given-names></name><name><surname>Nichols</surname><given-names>BE</given-names></name><name><surname>Mackey</surname><given-names>DA</given-names></name><name><surname>Ritch</surname><given-names>R</given-names></name><name><surname>Kalenak</surname><given-names>JW</given-names></name><name><surname>Craven</surname><given-names>ER</given-names></name><name><surname>Sheffield</surname><given-names>VC</given-names></name></person-group><article-title>Identification of a gene that causes primary open angle glaucoma.</article-title><source>Science</source><year>1997</year><volume>275</volume><fpage>668</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">9005853</pub-id></mixed-citation></ref><ref id="r12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stoilov</surname><given-names>I</given-names></name><name><surname>Akarsu</surname><given-names>AN</given-names></name><name><surname>Sarfarazi</surname><given-names>M</given-names></name></person-group><article-title>Identification of three different truncating mutations in cytochrome P4501B1 (CYP1B1) as the principal cause of primary congenital glaucoma (Buphthalmos) in families linked to the GLC3A locus on chromosome 2p21.</article-title><source>Hum Mol Genet</source><year>1997</year><volume>6</volume><fpage>641</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">9097971</pub-id></mixed-citation></ref><ref id="r13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rezaie</surname><given-names>T</given-names></name><name><surname>Child</surname><given-names>A</given-names></name><name><surname>Hitchings</surname><given-names>R</given-names></name><name><surname>Brice</surname><given-names>G</given-names></name><name><surname>Miller</surname><given-names>L</given-names></name><name><surname>Coca-Prados</surname><given-names>M</given-names></name><name><surname>Heon</surname><given-names>E</given-names></name><name><surname>Krupin</surname><given-names>T</given-names></name><name><surname>Ritch</surname><given-names>R</given-names></name><name><surname>Kreutzer</surname><given-names>D</given-names></name><name><surname>Crick</surname><given-names>RP</given-names></name><name><surname>Sarfarazi</surname><given-names>M</given-names></name></person-group><article-title>Adult-onset primary open-angle glaucoma caused by mutations in optineurin.</article-title><source>Science</source><year>2002</year><volume>295</volume><fpage>1077</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">11834836</pub-id></mixed-citation></ref><ref id="r14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fingert</surname><given-names>JH</given-names></name><name><surname>Heon</surname><given-names>E</given-names></name><name><surname>Liebmann</surname><given-names>JM</given-names></name><name><surname>Yamamoto</surname><given-names>T</given-names></name><name><surname>Craig</surname><given-names>JE</given-names></name><name><surname>Rait</surname><given-names>J</given-names></name><name><surname>Kawase</surname><given-names>K</given-names></name><name><surname>Hoh</surname><given-names>ST</given-names></name><name><surname>Buys</surname><given-names>YM</given-names></name><name><surname>Dickinson</surname><given-names>J</given-names></name><name><surname>Hockey</surname><given-names>RR</given-names></name><name><surname>Williams-Lyn</surname><given-names>D</given-names></name><name><surname>Trope</surname><given-names>G</given-names></name><name><surname>Kitazawa</surname><given-names>Y</given-names></name><name><surname>Ritch</surname><given-names>R</given-names></name><name><surname>Mackey</surname><given-names>DA</given-names></name><name><surname>Alward</surname><given-names>WL</given-names></name><name><surname>Sheffield</surname><given-names>VC</given-names></name><name><surname>Stone</surname><given-names>EM</given-names></name></person-group><article-title>Analysis of myocilin mutations in 1703 glaucoma patients from five different populations.</article-title><source>Hum Mol Genet</source><year>1999</year><volume>8</volume><fpage>899</fpage><lpage>905</lpage><pub-id pub-id-type="pmid">10196380</pub-id></mixed-citation></ref><ref id="r15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vincent</surname><given-names>AL</given-names></name><name><surname>Billingsley</surname><given-names>G</given-names></name><name><surname>Buys</surname><given-names>Y</given-names></name><name><surname>Levin</surname><given-names>AV</given-names></name><name><surname>Priston</surname><given-names>M</given-names></name><name><surname>Trope</surname><given-names>G</given-names></name><name><surname>Williams-Lyn</surname><given-names>D</given-names></name><name><surname>Heon</surname><given-names>E</given-names></name></person-group><article-title>Digenic inheritance of early-onset glaucoma: CYP1B1, a potential modifier gene.</article-title><source>Am J Hum Genet</source><year>2002</year><volume>70</volume><fpage>448</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">11774072</pub-id></mixed-citation></ref><ref id="r16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukhopadhyay</surname><given-names>A</given-names></name><name><surname>Acharya</surname><given-names>M</given-names></name><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Ray</surname><given-names>J</given-names></name><name><surname>Choudhury</surname><given-names>S</given-names></name><name><surname>Khan</surname><given-names>M</given-names></name><name><surname>Ray</surname><given-names>K</given-names></name></person-group><article-title>Mutations in MYOC gene of Indian primary open angle glaucoma patients.</article-title><source>Mol Vis</source><year>2002</year><volume>8</volume><fpage>442</fpage><lpage>8</lpage><ext-link ext-link-type="uri" xlink:href="http://www.molvis.org/molvis/v8/a53/">http://www.molvis.org/molvis/v8/a53/</ext-link><pub-id pub-id-type="pmid">12447164</pub-id></mixed-citation></ref><ref id="r17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanagavalli</surname><given-names>J</given-names></name><name><surname>Krishnadas</surname><given-names>SR</given-names></name><name><surname>Pandaranayaka</surname><given-names>E</given-names></name><name><surname>Krishnaswamy</surname><given-names>S</given-names></name><name><surname>Sundaresan</surname><given-names>P</given-names></name></person-group><article-title>Evaluation and understanding of myocilin mutations in Indian primary open angle glaucoma patients.</article-title><source>Mol Vis</source><year>2003</year><volume>9</volume><fpage>606</fpage><lpage>14</lpage><ext-link ext-link-type="uri" xlink:href="http://www.molvis.org/molvis/v9/a74/">http://www.molvis.org/molvis/v9/a74/</ext-link><pub-id pub-id-type="pmid">14627955</pub-id></mixed-citation></ref><ref id="r18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Markandaya</surname><given-names>M</given-names></name><name><surname>Ramesh</surname><given-names>TK</given-names></name><name><surname>Selvaraju</surname><given-names>V</given-names></name><name><surname>Dorairaj</surname><given-names>SK</given-names></name><name><surname>Prakash</surname><given-names>R</given-names></name><name><surname>Shetty</surname><given-names>J</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name></person-group><article-title>Genetic analysis of an Indian family with members affected with juvenile-onset primary open-angle glaucoma.</article-title><source>Ophthalmic Genet</source><year>2004</year><volume>25</volume><fpage>11</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">15255110</pub-id></mixed-citation></ref><ref id="r19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chakrabarti</surname><given-names>S</given-names></name><name><surname>Kaur</surname><given-names>K</given-names></name><name><surname>Komatireddy</surname><given-names>S</given-names></name><name><surname>Acharya</surname><given-names>M</given-names></name><name><surname>Devi</surname><given-names>KR</given-names></name><name><surname>Mukhopadhyay</surname><given-names>A</given-names></name><name><surname>Mandal</surname><given-names>AK</given-names></name><name><surname>Hasnain</surname><given-names>SE</given-names></name><name><surname>Chandrasekhar</surname><given-names>G</given-names></name><name><surname>Thomas</surname><given-names>R</given-names></name><name><surname>Ray</surname><given-names>K</given-names></name></person-group><article-title>Gln48His is the prevalent myocilin mutation in primary open angle and primary congenital glaucoma phenotypes in India.</article-title><source>Mol Vis</source><year>2005</year><volume>11</volume><fpage>111</fpage><lpage>3</lpage><ext-link ext-link-type="uri" xlink:href="http://www.molvis.org/molvis/v11/a12/">http://www.molvis.org/molvis/v11/a12/</ext-link><pub-id pub-id-type="pmid">15723004</pub-id></mixed-citation></ref><ref id="r20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Acharya</surname><given-names>M</given-names></name><name><surname>Mookherjee</surname><given-names>S</given-names></name><name><surname>Bhattacharjee</surname><given-names>A</given-names></name><name><surname>Bandyopadhyay</surname><given-names>AK</given-names></name><name><surname>Daulat Thakur</surname><given-names>SK</given-names></name><name><surname>Bhaduri</surname><given-names>G</given-names></name><name><surname>Sen</surname><given-names>A</given-names></name><name><surname>Ray</surname><given-names>K</given-names></name></person-group><article-title>Primary role of CYP1B1 in Indian juvenile-onset POAG patients.</article-title><source>Mol Vis</source><year>2006</year><volume>12</volume><fpage>399</fpage><lpage>404</lpage><ext-link ext-link-type="uri" xlink:href="http://www.molvis.org/molvis/v12/a46/">http://www.molvis.org/molvis/v12/a46/</ext-link><pub-id pub-id-type="pmid">16688110</pub-id></mixed-citation></ref><ref id="r21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukhopadhyay</surname><given-names>A</given-names></name><name><surname>Komatireddy</surname><given-names>S</given-names></name><name><surname>Acharya</surname><given-names>M</given-names></name><name><surname>Bhattacharjee</surname><given-names>A</given-names></name><name><surname>Mandal</surname><given-names>AK</given-names></name><name><surname>Thakur</surname><given-names>SK</given-names></name><name><surname>Chandrasekhar</surname><given-names>G</given-names></name><name><surname>Banerjee</surname><given-names>A</given-names></name><name><surname>Thomas</surname><given-names>R</given-names></name><name><surname>Chakrabarti</surname><given-names>S</given-names></name><name><surname>Ray</surname><given-names>K</given-names></name></person-group><article-title>Evaluation of Optineurin as a candidate gene in Indian patients with primary open angle glaucoma.</article-title><source>Mol Vis</source><year>2005</year><volume>11</volume><fpage>792</fpage><lpage>7</lpage><ext-link ext-link-type="uri" xlink:href="http://www.molvis.org/molvis/v11/a94/">http://www.molvis.org/molvis/v11/a94/</ext-link><pub-id pub-id-type="pmid">16205626</pub-id></mixed-citation></ref><ref id="r22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sripriya</surname><given-names>S</given-names></name><name><surname>Nirmaladevi</surname><given-names>J</given-names></name><name><surname>George</surname><given-names>R</given-names></name><name><surname>Hemamalini</surname><given-names>A</given-names></name><name><surname>Baskaran</surname><given-names>M</given-names></name><name><surname>Prema</surname><given-names>R</given-names></name><name><surname>Ve Ramesh</surname><given-names>S</given-names></name><name><surname>Karthiyayini</surname><given-names>T</given-names></name><name><surname>Amali</surname><given-names>J</given-names></name><name><surname>Job</surname><given-names>S</given-names></name><name><surname>Vijaya</surname><given-names>L</given-names></name><name><surname>Kumaramanickavel</surname><given-names>G</given-names></name></person-group><article-title>OPTN gene: profile of patients with glaucoma from India.</article-title><source>Mol Vis</source><year>2006</year><volume>12</volume><fpage>816</fpage><lpage>20</lpage><ext-link ext-link-type="uri" xlink:href="http://www.molvis.org/molvis/v12/a92/">http://www.molvis.org/molvis/v12/a92/</ext-link><pub-id pub-id-type="pmid">16885925</pub-id></mixed-citation></ref><ref id="r23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>JS</given-names></name><name><surname>Faucher</surname><given-names>M</given-names></name><name><surname>Hiscott</surname><given-names>P</given-names></name><name><surname>Biron</surname><given-names>VL</given-names></name><name><surname>Malenfant</surname><given-names>M</given-names></name><name><surname>Turcotte</surname><given-names>P</given-names></name><name><surname>Raymond</surname><given-names>V</given-names></name><name><surname>Walter</surname><given-names>MA</given-names></name></person-group><article-title>Protein localization in the human eye and genetic screen of opticin.</article-title><source>Hum Mol Genet</source><year>2002</year><volume>11</volume><fpage>1333</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">12019215</pub-id></mixed-citation></ref><ref id="r24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hauser</surname><given-names>MA</given-names></name><name><surname>Allingham</surname><given-names>RR</given-names></name><name><surname>Linkroum</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>LaRocque-Abramson</surname><given-names>K</given-names></name><name><surname>Figueiredo</surname><given-names>D</given-names></name><name><surname>Santiago-Turla</surname><given-names>C</given-names></name><name><surname>del Bono</surname><given-names>EA</given-names></name><name><surname>Haines</surname><given-names>JL</given-names></name><name><surname>Pericak-Vance</surname><given-names>MA</given-names></name><name><surname>Wiggs</surname><given-names>JL</given-names></name></person-group><article-title>Distribution of WDR36 DNA sequence variants in patients with primary open-angle glaucoma.</article-title><source>Invest Ophthalmol Vis Sci</source><year>2006</year><volume>47</volume><fpage>2542</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">16723468</pub-id></mixed-citation></ref><ref id="r25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bejjani</surname><given-names>BA</given-names></name><name><surname>Stockton</surname><given-names>DW</given-names></name><name><surname>Lewis</surname><given-names>RA</given-names></name><name><surname>Tomey</surname><given-names>KF</given-names></name><name><surname>Dueker</surname><given-names>DK</given-names></name><name><surname>Jabak</surname><given-names>M</given-names></name><name><surname>Astle</surname><given-names>WF</given-names></name><name><surname>Lupski</surname><given-names>JR</given-names></name></person-group><article-title>Multiple CYP1B1 mutations and incomplete penetrance in an inbred population segregating primary congenital glaucoma suggest frequent de novo events and a dominant modifier locus.</article-title><source>Hum Mol Genet</source><year>2000</year><volume>9</volume><fpage>367</fpage><lpage>74</lpage><comment>Erratum in: Hum Mol Genet 2000; 9:1141</comment><pub-id pub-id-type="pmid">10655546</pub-id></mixed-citation></ref><ref id="r26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panicker</surname><given-names>SG</given-names></name><name><surname>Reddy</surname><given-names>AB</given-names></name><name><surname>Mandal</surname><given-names>AK</given-names></name><name><surname>Ahmed</surname><given-names>N</given-names></name><name><surname>Nagarajaram</surname><given-names>HA</given-names></name><name><surname>Hasnain</surname><given-names>SE</given-names></name><name><surname>Balasubramanian</surname><given-names>D</given-names></name></person-group><article-title>Identification of novel mutations causing familial primary congenital glaucoma in Indian pedigrees.</article-title><source>Invest Ophthalmol Vis Sci</source><year>2002</year><volume>43</volume><fpage>1358</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">11980847</pub-id></mixed-citation></ref><ref id="r27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colomb</surname><given-names>E</given-names></name><name><surname>Kaplan</surname><given-names>J</given-names></name><name><surname>Garchon</surname><given-names>HJ</given-names></name></person-group><article-title>Novel cytochrome P450 1B1 (CYP1B1) mutations in patients with primary congenital glaucoma in France.</article-title><source>Hum Mutat</source><year>2003</year><volume>22</volume><fpage>496</fpage><pub-id pub-id-type="pmid">14635112</pub-id></mixed-citation></ref><ref id="r28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reddy</surname><given-names>AB</given-names></name><name><surname>Panicker</surname><given-names>SG</given-names></name><name><surname>Mandal</surname><given-names>AK</given-names></name><name><surname>Hasnain</surname><given-names>SE</given-names></name><name><surname>Balasubramanian</surname><given-names>D</given-names></name></person-group><article-title>Identification of R368H as a predominant CYP1B1 allele causing primary congenital glaucoma in Indian patients.</article-title><source>Invest Ophthalmol Vis Sci</source><year>2003</year><volume>44</volume><fpage>4200</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">14507861</pub-id></mixed-citation></ref><ref id="r29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alward</surname><given-names>WL</given-names></name><name><surname>Fingert</surname><given-names>JH</given-names></name><name><surname>Coote</surname><given-names>MA</given-names></name><name><surname>Johnson</surname><given-names>AT</given-names></name><name><surname>Lerner</surname><given-names>SF</given-names></name><name><surname>Junqua</surname><given-names>D</given-names></name><name><surname>Durcan</surname><given-names>FJ</given-names></name><name><surname>McCartney</surname><given-names>PJ</given-names></name><name><surname>Mackey</surname><given-names>DA</given-names></name><name><surname>Sheffield</surname><given-names>VC</given-names></name><name><surname>Stone</surname><given-names>EM</given-names></name></person-group><article-title>Clinical features associated with mutations in the chromosome 1 open-angle glaucoma gene (GLC1A).</article-title><source>N Engl J Med</source><year>1998</year><volume>338</volume><fpage>1022</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">9535666</pub-id></mixed-citation></ref><ref id="r30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>BJ</given-names></name><name><surname>Leung</surname><given-names>YF</given-names></name><name><surname>Pang</surname><given-names>CP</given-names></name><name><surname>Baum</surname><given-names>L</given-names></name><name><surname>Tam</surname><given-names>OS</given-names></name><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Lam</surname><given-names>SC</given-names></name></person-group><article-title>Single nucleotide polymorphisms of the myocilin gene in primary open-angle glaucoma patients.</article-title><source>Zhonghua Yi Xue Yi Chuan Xue Za Zhi</source><year>2004</year><volume>21</volume><fpage>70</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">14767915</pub-id></mixed-citation></ref><ref id="r31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>DY</given-names></name><name><surname>Fan</surname><given-names>BJ</given-names></name><name><surname>Canlas</surname><given-names>O</given-names></name><name><surname>Tam</surname><given-names>PO</given-names></name><name><surname>Ritch</surname><given-names>R</given-names></name><name><surname>Lam</surname><given-names>DS</given-names></name><name><surname>Fan</surname><given-names>DS</given-names></name><name><surname>Pang</surname><given-names>CP</given-names></name></person-group><article-title>Absence of myocilin and optineurin mutations in a large Philippine family with juvenile onset primary open angle glaucoma.</article-title><source>Mol Vis</source><year>2004</year><volume>10</volume><fpage>851</fpage><lpage>6</lpage><ext-link ext-link-type="uri" xlink:href="http://www.molvis.org/molvis/v10/a102/">http://www.molvis.org/molvis/v10/a102/</ext-link><pub-id pub-id-type="pmid">15547491</pub-id></mixed-citation></ref><ref id="r32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Funayama</surname><given-names>T</given-names></name><name><surname>Ishikawa</surname><given-names>K</given-names></name><name><surname>Ohtake</surname><given-names>Y</given-names></name><name><surname>Tanino</surname><given-names>T</given-names></name><name><surname>Kurosaka</surname><given-names>D</given-names></name><name><surname>Kimura</surname><given-names>I</given-names></name><name><surname>Suzuki</surname><given-names>K</given-names></name><name><surname>Ideta</surname><given-names>H</given-names></name><name><surname>Nakamoto</surname><given-names>K</given-names></name><name><surname>Yasuda</surname><given-names>N</given-names></name><name><surname>Fujimaki</surname><given-names>T</given-names></name><name><surname>Murakami</surname><given-names>A</given-names></name><name><surname>Asaoka</surname><given-names>R</given-names></name><name><surname>Hotta</surname><given-names>Y</given-names></name><name><surname>Tanihara</surname><given-names>H</given-names></name><name><surname>Kanamoto</surname><given-names>T</given-names></name><name><surname>Mishima</surname><given-names>H</given-names></name><name><surname>Fukuchi</surname><given-names>T</given-names></name><name><surname>Abe</surname><given-names>H</given-names></name><name><surname>Iwata</surname><given-names>T</given-names></name><name><surname>Shimada</surname><given-names>N</given-names></name><name><surname>Kudoh</surname><given-names>J</given-names></name><name><surname>Shimizu</surname><given-names>N</given-names></name><name><surname>Mashima</surname><given-names>Y</given-names></name></person-group><article-title>Variants in optineurin gene and their association with tumor necrosis factor-alpha polymorphisms in Japanese patients with glaucoma.</article-title><source>Invest Ophthalmol Vis Sci</source><year>2004</year><volume>45</volume><fpage>4359</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">15557444</pub-id></mixed-citation></ref><ref id="r33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuse</surname><given-names>N</given-names></name><name><surname>Takahashi</surname><given-names>K</given-names></name><name><surname>Akiyama</surname><given-names>H</given-names></name><name><surname>Nakazawa</surname><given-names>T</given-names></name><name><surname>Seimiya</surname><given-names>M</given-names></name><name><surname>Kuwahara</surname><given-names>S</given-names></name><name><surname>Tamai</surname><given-names>M</given-names></name></person-group><article-title>Molecular genetic analysis of optineurin gene for primary open-angle and normal tension glaucoma in the Japanese population.</article-title><source>J Glaucoma</source><year>2004</year><volume>13</volume><fpage>299</fpage><lpage>303</lpage><pub-id pub-id-type="pmid">15226658</pub-id></mixed-citation></ref><ref id="r34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ayala-Lugo</surname><given-names>RM</given-names></name><name><surname>Pawar</surname><given-names>H</given-names></name><name><surname>Reed</surname><given-names>DM</given-names></name><name><surname>Lichter</surname><given-names>PR</given-names></name><name><surname>Moroi</surname><given-names>SE</given-names></name><name><surname>Page</surname><given-names>M</given-names></name><name><surname>Eadie</surname><given-names>J</given-names></name><name><surname>Azocar</surname><given-names>V</given-names></name><name><surname>Maul</surname><given-names>E</given-names></name><name><surname>Ntim-Amponsah</surname><given-names>C</given-names></name><name><surname>Bromley</surname><given-names>W</given-names></name><name><surname>Obeng-Nyarkoh</surname><given-names>E</given-names></name><name><surname>Johnson</surname><given-names>AT</given-names></name><name><surname>Kijek</surname><given-names>TG</given-names></name><name><surname>Downs</surname><given-names>CA</given-names></name><name><surname>Johnson</surname><given-names>JM</given-names></name><name><surname>Perez-Grossmann</surname><given-names>RA</given-names></name><name><surname>Guevara-Fujita</surname><given-names>ML</given-names></name><name><surname>Fujita</surname><given-names>R</given-names></name><name><surname>Wallace</surname><given-names>MR</given-names></name><name><surname>Richards</surname><given-names>JE</given-names></name></person-group><article-title>Variation in optineurin (OPTN) allele frequencies between and within populations.</article-title><source>Mol Vis</source><year>2007</year><volume>13</volume><fpage>151</fpage><lpage>63</lpage><ext-link ext-link-type="uri" xlink:href="http://www.molvis.org/molvis/v13/a18/">http://www.molvis.org/molvis/v13/a18/</ext-link><pub-id pub-id-type="pmid">17293779</pub-id></mixed-citation></ref><ref id="r35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weisschuh</surname><given-names>N</given-names></name><name><surname>Neumann</surname><given-names>D</given-names></name><name><surname>Wolf</surname><given-names>C</given-names></name><name><surname>Wissinger</surname><given-names>B</given-names></name><name><surname>Gramer</surname><given-names>E</given-names></name></person-group><article-title>Prevalence of myocilin and optineurin sequence variants in German normal tension glaucoma patients.</article-title><source>Mol Vis</source><year>2005</year><volume>11</volume><fpage>284</fpage><lpage>7</lpage><ext-link ext-link-type="uri" xlink:href="http://www.molvis.org/molvis/v11/a33/">http://www.molvis.org/molvis/v11/a33/</ext-link><pub-id pub-id-type="pmid">15851979</pub-id></mixed-citation></ref><ref id="r36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname><given-names>YF</given-names></name><name><surname>Fan</surname><given-names>BJ</given-names></name><name><surname>Lam</surname><given-names>DS</given-names></name><name><surname>Lee</surname><given-names>WS</given-names></name><name><surname>Tam</surname><given-names>PO</given-names></name><name><surname>Chua</surname><given-names>JK</given-names></name><name><surname>Tham</surname><given-names>CC</given-names></name><name><surname>Lai</surname><given-names>JS</given-names></name><name><surname>Fan</surname><given-names>DS</given-names></name><name><surname>Pang</surname><given-names>CP</given-names></name></person-group><article-title>Different optineurin mutation pattern in primary open-angle glaucoma.</article-title><source>Invest Ophthalmol Vis Sci</source><year>2003</year><volume>44</volume><fpage>3880</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">12939304</pub-id></mixed-citation></ref><ref id="r37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toda</surname><given-names>Y</given-names></name><name><surname>Tang</surname><given-names>S</given-names></name><name><surname>Kashiwagi</surname><given-names>K</given-names></name><name><surname>Mabuchi</surname><given-names>F</given-names></name><name><surname>Iijima</surname><given-names>H</given-names></name><name><surname>Tsukahara</surname><given-names>S</given-names></name><name><surname>Yamagata</surname><given-names>Z</given-names></name></person-group><article-title>Mutations in the optineurin gene in Japanese patients with primary open-angle glaucoma and normal tension glaucoma.</article-title><source>Am J Med Genet A</source><year>2004</year><volume>125</volume><fpage>1</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">14755458</pub-id></mixed-citation></ref><ref id="r38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alward</surname><given-names>WL</given-names></name><name><surname>Kwon</surname><given-names>YH</given-names></name><name><surname>Kawase</surname><given-names>K</given-names></name><name><surname>Craig</surname><given-names>JE</given-names></name><name><surname>Hayreh</surname><given-names>SS</given-names></name><name><surname>Johnson</surname><given-names>AT</given-names></name><name><surname>Khanna</surname><given-names>CL</given-names></name><name><surname>Yamamoto</surname><given-names>T</given-names></name><name><surname>Mackey</surname><given-names>DA</given-names></name><name><surname>Roos</surname><given-names>BR</given-names></name><name><surname>Affatigato</surname><given-names>LM</given-names></name><name><surname>Sheffield</surname><given-names>VC</given-names></name><name><surname>Stone</surname><given-names>EM</given-names></name></person-group><article-title>Evaluation of optineurin sequence variations in 1,048 patients with open-angle glaucoma.</article-title><source>Am J Ophthalmol</source><year>2003</year><volume>136</volume><fpage>904</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">14597044</pub-id></mixed-citation></ref><ref id="r39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melki</surname><given-names>R</given-names></name><name><surname>Belmouden</surname><given-names>A</given-names></name><name><surname>Akhayat</surname><given-names>O</given-names></name><name><surname>Brezin</surname><given-names>A</given-names></name><name><surname>Garchon</surname><given-names>HJ</given-names></name></person-group><article-title>The M98K variant of the OPTINEURIN (OPTN) gene modifies initial intraocular pressure in patients with primary open angle glaucoma.</article-title><source>J Med Genet</source><year>2003</year><volume>40</volume><fpage>842</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">14627677</pub-id></mixed-citation></ref><ref id="r40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aklillu</surname><given-names>E</given-names></name><name><surname>Oscarson</surname><given-names>M</given-names></name><name><surname>Hidestrand</surname><given-names>M</given-names></name><name><surname>Leidvik</surname><given-names>B</given-names></name><name><surname>Otter</surname><given-names>C</given-names></name><name><surname>Ingelman-Sundberg</surname><given-names>M</given-names></name></person-group><article-title>Functional analysis of six different polymorphic CYP1B1 enzyme variants found in an Ethiopian population.</article-title><source>Mol Pharmacol</source><year>2002</year><volume>61</volume><fpage>586</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">11854439</pub-id></mixed-citation></ref><ref id="r41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>R</given-names></name><name><surname>Hattori</surname><given-names>Y</given-names></name><name><surname>Okano</surname><given-names>K</given-names></name></person-group><article-title>Promoter mutations of myocilin gene in Japanese patients with open angle glaucoma including normal tension glaucoma.</article-title><source>Br J Ophthalmol</source><year>2000</year><volume>84</volume><fpage>1078</fpage><pub-id pub-id-type="pmid">11032443</pub-id></mixed-citation></ref><ref id="r42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willoughby</surname><given-names>CE</given-names></name><name><surname>Chan</surname><given-names>LL</given-names></name><name><surname>Herd</surname><given-names>S</given-names></name><name><surname>Billingsley</surname><given-names>G</given-names></name><name><surname>Noordeh</surname><given-names>N</given-names></name><name><surname>Levin</surname><given-names>AV</given-names></name><name><surname>Buys</surname><given-names>Y</given-names></name><name><surname>Trope</surname><given-names>G</given-names></name><name><surname>Sarfarazi</surname><given-names>M</given-names></name><name><surname>Heon</surname><given-names>E</given-names></name></person-group><article-title>Defining the pathogenicity of optineurin in juvenile open-angle glaucoma.</article-title><source>Invest Ophthalmol Vis Sci</source><year>2004</year><volume>45</volume><fpage>3122</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">15326130</pub-id></mixed-citation></ref><ref id="r43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alward</surname><given-names>WL</given-names></name><name><surname>Kwon</surname><given-names>YH</given-names></name><name><surname>Khanna</surname><given-names>CL</given-names></name><name><surname>Johnson</surname><given-names>AT</given-names></name><name><surname>Hayreh</surname><given-names>SS</given-names></name><name><surname>Zimmerman</surname><given-names>MB</given-names></name><name><surname>Narkiewicz</surname><given-names>J</given-names></name><name><surname>Andorf</surname><given-names>JL</given-names></name><name><surname>Moore</surname><given-names>PA</given-names></name><name><surname>Fingert</surname><given-names>JH</given-names></name><name><surname>Sheffield</surname><given-names>VC</given-names></name><name><surname>Stone</surname><given-names>EM</given-names></name></person-group><article-title>Variations in the myocilin gene in patients with open-angle glaucoma.</article-title><source>Arch Ophthalmol</source><year>2002</year><volume>120</volume><fpage>1189</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">12215093</pub-id></mixed-citation></ref><ref id="r44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozgul</surname><given-names>RK</given-names></name><name><surname>Bozkurt</surname><given-names>B</given-names></name><name><surname>Orcan</surname><given-names>S</given-names></name><name><surname>Bulur</surname><given-names>B</given-names></name><name><surname>Bagiyeva</surname><given-names>S</given-names></name><name><surname>Irkec</surname><given-names>M</given-names></name><name><surname>Ogus</surname><given-names>A</given-names></name></person-group><article-title>Myocilin mt1 promoter polymorphism in Turkish patients with primary open angle glaucoma.</article-title><source>Mol Vis</source><year>2005</year><volume>11</volume><fpage>916</fpage><lpage>21</lpage><ext-link ext-link-type="uri" xlink:href="http://www.molvis.org/molvis/v11/a109/">http://www.molvis.org/molvis/v11/a109/</ext-link><pub-id pub-id-type="pmid">16280977</pub-id></mixed-citation></ref></ref-list></back></article>